The Lift Line

A country diagnoses the health of its women in the length of time it takes to name what is wrong with them. Twelve years is a verdict.

Why This Editorial Matters for Your Exam

Women’s health and reproductive rights are a recurring GS 1 and GS 2 examination area, and endometriosis has now entered current affairs with India’s first genome-wide association study of the condition. The examinable material is not the biology, it is the intersection of gender bias, health infrastructure and public policy, which is where marks are decided. This editorial does that intersection cleanly.

GS Paper 1: Salient features of Indian Society; role of women and women’s organisation. GS Paper 2: Issues relating to development and management of Social Sector or Services relating to Health.

Concept Meaning Why it is testable
Genome-wide association study (GWAS) A method that scans complete genomes to identify genetic variants associated with a disease The scientific instrument of the reported breakthrough
Endometriosis A chronic condition in which tissue similar to the uterine lining grows outside the uterus, causing chronic pelvic pain, infertility and organ damage Underdiagnosed globally; the delay is the story
Ancestry bias in genetic research Overrepresentation of European ancestry in genomic databases, which limits generalisability to South Asian populations The equity case for Indian GWAS work
Reproductive autoimmune disorders Autoimmune conditions in which hormonal fluctuations trigger or aggravate systemic inflammation Named in the piece; part of the same diagnostic-delay problem

Background and Context

This is a signed opinion column by Sukhmani Malik, sub-editor at The Indian Express, under the fortnightly ‘She Said’ column curated by Shalini Langer. The occasion is the reported publication of India’s first genome-wide study of endometriosis, which begins to address the long-standing underrepresentation of South Asian ancestry in the international genetic literature on reproductive-health conditions.

Endometriosis is a chronic gynaecological condition in which tissue similar to the endometrium (the tissue that lines the inside of the uterus) grows outside it, on the ovaries, fallopian tubes and other pelvic structures. It causes chronic pelvic pain, dysmenorrhoea, infertility and, in advanced cases, organ damage. The World Health Organization estimates that endometriosis affects roughly 190 million women and girls of reproductive age globally, about 10 per cent. Diagnostic delays are widely reported in the international literature to run from seven to 12 years, and the definitive diagnosis has traditionally required laparoscopy with histological confirmation.

The Analysis

1. Why South Asian genomes matter for reproductive-health research. International genomic databases have historically overrepresented European ancestry. When risk loci for a complex condition are identified in that dominant sample, their applicability to other populations is a testable question, not an assumption. A South Asia focused genome-wide association study of endometriosis therefore does two things at once: it looks for the loci relevant to Indian patients and it enlarges the reference base for downstream diagnostic and therapeutic work.

2. The clinical delay is measurable and it is not new. The international literature has repeatedly established that endometriosis is diagnosed on average seven to 12 years after symptom onset. That is not a limitation of science alone; it is the compound of normalised menstrual pain, low index of suspicion in primary care, symptom overlap with irritable bowel syndrome and PCOS, and the historical reliance on laparoscopy for definitive diagnosis. In each of those steps, gendered assumptions can add to the delay rather than mitigate it.

3. History casts a long shadow. The piece opens on the long history of classifying women’s illnesses as “hysteria”, an umbrella diagnosis in western medicine from Hippocratic writings through the 19th century with essentially no therapeutic content. That legacy did not end cleanly; the tendency to attribute women’s pelvic and chronic pain to psychological causation persisted well into the 20th century and remains a documented risk in clinical encounters.

4. Menstrual taboo compresses the reporting window. In India, in particular, menstruation is still treated as a topic on which speech is restricted, in the household, in the school and in the workplace. The consequence is that the interval between symptom onset and a first informed conversation with a clinician is longer than it should be, and the first conversation is often incomplete. Programmes like the Rashtriya Kishor Swasthya Karyakram (RKSK) and menstrual-hygiene management under Swachh Bharat address one part of this pipeline, but the reproductive-pain conversation, distinct from hygiene, is under-served.

5. The private and social costs compound quickly. A diagnosis years late (the writer cites a friend diagnosed only after 12 years), in a condition that can damage the ovaries, bladder and bowel, is not a soft cost. For the novelist Hilary Mantel, quoted in the piece, “the payment for the diagnosis was ‘part of my bladder and my bowel, my womb and my ovaries.’” That is life-altering morbidity. Multiplied across the estimated tens of millions of Indian women affected, the aggregate cost, in disability-adjusted life years and in lost workforce participation, is substantial.

6. Adjacent conditions carry the same pattern. Polyendocrine metabolic ovarian syndrome (PMOS, formerly PCOS), premenstrual dysphoric disorder, endometriosis and reproductive-autoimmune conditions share diagnostic-delay patterns, symptom-normalisation dynamics and treatment neglect. Framing the endometriosis story as a stand-alone breakthrough understates that the underlying culture is common across the group.

7. The policy levers are already available. The Indian Council of Medical Research (ICMR) funds priority-condition task forces. The Department of Biotechnology (DBT) funds genomics work. The Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY) provides insurance cover; the Ayushman Arogya Mandirs (formerly Health and Wellness Centres) provide primary care. The National Medical Commission (NMC) sets the MBBS curriculum. Reforming the diagnosis-delay pipeline requires each of these to move rather than any single dramatic intervention.

8. What the science does not do on its own. A genome-wide risk map, however comprehensive, does not by itself shorten the interval between a first period-pain episode and a first specialist appointment. That interval is a function of household culture, school health education, primary-care training and referral pathways. The science is a lever; it is not the outcome.

Data and Institutions Vault

Prelims-grade facts:

The condition:

  • Endometriosis affects roughly 190 million women and girls of reproductive age globally, about 10 per cent (WHO estimate).
  • The average diagnostic delay is 7 to 12 years, per international clinical literature.
  • Definitive diagnosis has traditionally required laparoscopy with histological confirmation.
  • Advanced disease causes chronic pelvic pain, dysmenorrhoea, infertility and pelvic organ damage.

The science:

  • India’s first genome-wide association study of endometriosis begins to correct the historical overrepresentation of European ancestry in genomic databases.
  • Genome-wide association studies scan complete genomes to identify variants associated with disease risk.
  • PCOS was renamed polyendocrine metabolic ovarian syndrome (PMOS) in 2026.
  • Related reproductive-health conditions include PMOS, premenstrual dysphoric disorder and reproductive autoimmune disease.

Institutions and programmes:

  • Indian Council of Medical Research (ICMR): apex body for biomedical research policy in India; runs condition-specific task forces.
  • Department of Biotechnology (DBT): funder of the Genome India Programme and other population-genomics work.
  • National Medical Commission (NMC): statutory body regulating medical education and the MBBS curriculum, established by the National Medical Commission Act, 2019.
  • Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY): flagship health insurance scheme, insurance cover up to Rs 5 lakh per family per year.
  • Rashtriya Kishor Swasthya Karyakram (RKSK): the adolescent-health programme under the National Health Mission.

The gender-in-medicine backdrop:

  • “Hysteria” was used as an umbrella diagnosis for women’s physical and mental illness from antiquity through the 19th century, without therapeutic content.
  • Author Hilary Mantel’s 2004 essay documented endometriosis diagnostic delay and organ loss.
  • Menstrual taboo in India shortens the interval to a first informed clinical conversation about reproductive pain.

Watch the trap: the genome-wide association study is a research method, not a diagnostic tool. A woman does not walk into a hospital and get a GWAS. The breakthrough is the reference base, not the point-of-care instrument.

The Debate

FOR reading this as primarily a scientific breakthrough: India’s first genome-wide association study on endometriosis is a genuine capability advance; South Asian ancestry has been chronically underrepresented in international genomic databases, and correcting that is a precondition for any downstream diagnostic or therapeutic work relevant to Indian patients. On this reading, the appropriate reform priorities are research funding, biobanking and follow-on translational work.

AGAINST reading it as only a scientific story: The piece argues that scientific advance without clinical and cultural change will not shorten the 12-year diagnostic delay for the next generation. The bottleneck is at the primary-care level, at the household level and in the school; a GWAS does not open any of those. On this reading, the priorities are curriculum, referral pathways and menstrual-health awareness, and the science is a supplement rather than a substitute.

Balanced verdict: Both are correct on different time horizons. The GWAS is a necessary capability build for the next decade of Indian reproductive-health research. The diagnosis-delay problem is a present-tense clinical culture problem, and it needs curriculum reform, specialist referral pathways within Ayushman Bharat, a national endometriosis registry with delay reporting, and menstrual-pain modules in RKSK that treat pain as a symptom to be investigated rather than tolerated. Move on both fronts, and the science eventually pays off in years saved rather than in papers published.

How to Think About This

For any health-policy question in which a scientific breakthrough meets a service-delivery failure, ask three sequential questions. First, is the population for whom the breakthrough was made the population who most needed it? A study on South Asian ancestry corrects a coverage gap. Second, is there a pathway from the breakthrough to the point of care that any patient can travel? A GWAS without primary-care follow-through does not close a diagnosis delay. Third, are the non-clinical determinants, in this case social and cultural, being moved at the same time? A patient who cannot say “I am in pain” does not benefit from a risk-locus map. A reform proposal that answers all three passes the coherence test.

Diagram-in-Words

Symptom onset menstrual taboo household silence Primary care low awareness pain minimisation Specialist referral laparoscopy histology Diagnosis 7 to 12 years after onset Policy levers to shorten each stage RKSK adolescent health reproductive pain modules in schools MBBS curriculum NMC standards gender-sensitive pain modules AB-PMJAY specialist referral pathway package for pelvic pain ICMR registry endometriosis delay reporting GWAS follow-up The science is a lever, not the outcome GWAS enlarges the reference base; the delay closes only when all four levers move together
The 12-year delay is a pipeline, not a moment. Each stage is a distinct policy problem, and the genome-wide study only lengthens the reference base at the far right. To shorten total time to diagnosis, all four levers must move together.

PYQ Linkage

  • UPSC CSE Mains 2017, GS1: “The women’s questions arose in modern India as a part of the 19th century social reform movement. What were the major issues and debates concerning women in that period?” Reads across the long-standing pattern of women’s health receiving late clinical attention.
  • UPSC CSE Mains 2015, GS2: “Public health system has limitations in providing universal health coverage. Do you think that the private sector could help in bridging the gap? What other viable alternatives would you suggest?” Applies to the specialist-referral shortfall for endometriosis and PCOS. Sources: Indian Express, ICMR, Ministry of Health and Family Welfare, WHO

Source: Listen to Women in Pain: What India's First Genome-Wide Endometriosis Study Should Change — Ujiyari.com | Free UPSC & State PCS Editorial Analysis